Recruiting

Observational Study

Sponsor:

Ohio State University Comprehensive Cancer Center

Code:

NCT01408225

Conditions

Plasma Cell Dyscrasias

Monoclonal Gammopathy of Undetermined Significance

AL Amyloidosis

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

tissue banking

Study Details

Brief summary:

The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals:

  • Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live.
  • Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups.
  • Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.

Conditions

Plasma Cell Dyscrasias

Monoclonal Gammopathy of Undetermined Significance

AL Amyloidosis

Multiple Myeloma

Study ID

NCT01408225

Start date

Mar 17, 2011

Status verified date

Mar, 2026

Completion date

Mar, 2050

Anticipated

Primary completion date

Mar, 2050

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion:

Diagnosis of a plasma cell dyscrasia

Exclusion:

Prisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol.

Study Design

Enrollment

5000 participants

Anticipated

Interventions and Outcome Measures

Interventions

tissue banking

tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.

Primary outcome measure

  • Develop a data and sample resource that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality of patients diagnosed or living with Multiple Myeloma in the state of Ohio [ Time Frame: up to 3 years ]

Central Contacts and Locations

Central contacts

The Ohio State University Comprehensive Cancer Center

1-800-293-5066OSUCCCClinicaltrials@osumc.edu

Locations

Ohio State University Medical Center

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Principal Investigator:

Don Benson, MD

More Information

Sponsor

Ohio State University Comprehensive Cancer Center

Last update posted

Mar 23, 2026

Last verified

Mar, 2026

Keywords

  • MGUS
  • Multiple Myeloma
  • Tissue Bank

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center on 2026-03-23.